The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial
Abstract
BACKGROUND: Treatment of acute antibody-mediated rejection (AMR) is based on a combination of plasma exchange (PE), IVIg, corticosteroids (CS), and rituximab, but the place of rituximab is not clearly specified in the absence of randomized trials. METHODS: In this phase III, multicenter, double-blind, placebo-controlled trial, we randomly assigned patients with biopsy-proven AMR to receive rituximab (375 mg/m) or placebo at day 5. All patients received PE, IVIg, and CS. The primary endpoint was a composite of graft loss or no improvement in renal function at day 12. RESULTS: Among the 38 patients included, at 1 year, no deaths occurred, but 1 graft loss occurred in each group. The primary endpoint frequency was 52.6% (10/19) and 57.9% (11/19) in the rituximab and placebo groups, respectively (P = 0.744). Renal function improved in both groups, as soon as day 12 with no difference in serum creatinine level and proteinuria at 1, 3, 6, and 12 months. Supplementary administration of rituximab and total number of IVIg and PE treatments did not differ between the 2 groups. Both groups showed improved histological features of AMR and Banff scores at 1 and 6 months, with no significant difference between groups but with a trend in favor of the rituximab group. Both groups showed decreased mean fluorescence intensity of donor-specific antibodies as soon as day 12, with no significant difference between them but with a trend in favor of the rituximab group at 12 months. CONCLUSIONS: After 1 year of follow-up, we observed no additional effect of rituximab in patients receiving PE, IVIg, and CS for AMR. Nevertheless, our study was underpowered and important differences between groups may have been missed. Complementary trials with long-term follow-up are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rejection of the Kidney Allograft
Nankivell, B. J., & Alexander, S. I. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0902927 · Cited by 605
Cited by
Long-Term Survival after Kidney Transplantation
Hariharan, S., Israni, A. K., & Danovitch, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2014530 · Cited by 664
Antibody-Mediated Rejection of Solid-Organ Allografts
Loupy, A., & Lefaucheur, C. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1802677 · Cited by 549
Diagnosis and Management of Antibody-Mediated Rejection: Current Status and Novel Approaches
Djamali, A., Kaufman, D. B., Ellis, T. M., Zhong, W., Matas, A., & Samaniego, M. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12589 · Cited by 369
Loupy, A., Aubert, O., Orandi, B. J., Naesens, M., Bouatou, Y., Raynaud, M., Divard, G., Jackson, A. M., Viglietti, D., Giral, M., et al. (2019) · BMJ · doi:10.1136/bmj.l4923 · Cited by 350
Self-citationSchinstock, C. A., Mannon, R. B., Budde, K., Chong, A. S., Haas, M., Knechtle, S., Lefaucheur, C., Montgomery, R. A., Nickerson, P., Tullius, S. G., et al. (2020) · Transplantation · doi:10.1097/tp.0000000000003095 · Cited by 345
Metadata
- Authors
- Sautenet, B., Blancho, G., Büchler, M., Morelon, E., Toupance, O., Barrou, B., Ducloux, D., Chatelet, V., Moulin, B., Freguin, C., Hazzan, M., Lang, P., Legendre, C., Merville, P., Mourad, G., Mousson, C., Pouteil-Noble, C., Purgus, R., Rerolle, J.-P., Sayegh, J., Westeel, P.-F., Zaoui, P., Boivin, H., Le Gouge, A., & Lebranchu, Y.
- Venue
- Transplantation
- Published
- 2016-02
- Volume
- 100
- Issue
- 2
- Pages
- 391-399
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2129422323
- Cited by
- 187
- References
- 1
- FWCI
- 16.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial. https://app.cochat.ai/papers/10.1097/tp.0000000000000958
- The paper
- Sautenet, B., Blancho, G., Büchler, M., Morelon, E., Toupance, O., Barrou, B., Ducloux, D., Chatelet, V., Moulin, B., Freguin, C., Hazzan, M., Lang, P., Legendre, C., Merville, P., Mourad, G., Mousson, C., Pouteil-Noble, C., Purgus, R., Rerolle, J.-P., . . . Lebranchu, Y. (2016). One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial. Transplantation. https://doi.org/10.1097/tp.0000000000000958
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.